Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides
AssigneeConjuChem Biotechnologies Inc.
InventorsDominique P. Bridon, Robert P. Dufresne, Nissab Boudjellab, Martin Robitaille, Peter G. Milner
Life of this patent
Estimating the term…
Abstract
Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
Claims47
An antifusogenic peptide-albumin conjugate comprising:
- an anti-fusogenic peptide comprising a maleimide containing group and an amino acid sequence, wherein said sequence is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 117, SEQ ID NO:
- 118, SEQ ID NO:
- 119, SEQ ID NO:
- 534, SEQ ID NO:
- 535, SEQ ID NO:
- 536, SEQ ID NO:
- 537, SEQ ID NO:
- 538, SEQ ID NO:
- 539, SEQ ID NO:
- 540, and SEQ ID NO:
- 541, wherein said sequence exhibits an anti-viral and antifusogenic activity against human immunodeficiency virus (HIV) and said peptide is covalently bonded to cysteine 34 of albumin through said maleimide containing group to form said peptide-albumin conjugate wherein the ratio of peptide to albumin in said conjugate is 1:1, and wherein said maleimide containing group is attached to said peptide without a linker or via a (2-amino)ethoxy acetic acid (AEA) or a [2-(2-amino) ethoxy] acetic acid (AEEA) linker.
A composition for use in the treatment of acquired immune deficiency syndrome (AIDS) comprising, in a physiologically acceptable medium, an anti-fusogenic peptide-albumin conjugate comprising an anti-fusogenic peptide comprising a maleimide containing group and an amino acid sequence wherein said sequence is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 117, SEQ ID NO:
- 118, SEQ ID NO:
- 119, SEQ ID NO:
- 534, SEQ ID NO:
- 535, SEQ ID NO:
- 536, SEQ ID NO:
- 537, SEQ ID NO:
- 538, SEQ ID NO:
- 539, SEQ ID NO:
- 540, and SEQ ID NO:
- 541, wherein said sequence inhibits an anti-viral and anti-fusogenic activity against human immunodeficiency virus (HIV) and said peptide is covalently bonded to cysteine 34 of albumin through said maleimide containing group to form said anti-viral peptide-albumin conjugate, wherein the ratio of peptide to albumin in said conjugate is 1:1, wherein said maleimide containing group is attached to said peptide without a linker or via a (2-amino)ethoxy acetic acid (AEA) or a [2-(2-amino) ethoxy] acetic acid (AEEA) linker.
Dependencies are inferred from the claim text.